Anti-Factor VIII, Recombinant [RFF-VIII:c/8]
Invented at University College London
- Datasheet
- References (1)
- Inventor Info
Info
| Catalogue Number | 153358 |
| Applications | IF Fn WB |
| Antigen/Gene or Protein Targets | Factor VIII |
| Reactivity | Human |
| Relevance | The commonest severe congenital bleeding disorder in all races is haemophilia A. The characteristic defect is a lack of coagulation factor VIII:C. Factor VIII:C is a glycoprotein that functions as a cofactor for factor IXa which, in the presence of calcium and phospholipids, converts factor X to the activated form Xa. This antibody binds to human FVIII:C heavy chain and inhibits its function. |
| Host | Mouse |
| Immunogen | Purified human factor VIII |
| Subclass | IgG1 kappa |
| Formulation | PBS |
| Concentration | 1mg/ml |
| Research Area | Cardiovascular |
| Notes | Recombinant monoclonal antibody produced from the original monoclonal. Manufactured using Absolute Antibody’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma. |
References: 1 entry
Original hybridoma first published in: Rotblat et al. 1983. J Lab Clin Med. 101(5):736-46. PMID: 6403638.
Add a reference
References: 1 entry
Original hybridoma first published in: Rotblat et al. 1983. J Lab Clin Med. 101(5):736-46. PMID: 6403638.
Add a reference
